{"doi":"10.1007/s10147-017-1141-y","title":"Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy","abstract":null,"journal":"International Journal of Clinical Oncology","year":2017,"id":624672,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1614889,"name":"Chikashi Yoshida","orcid":null,"position":1,"is_corresponding":false},{"id":1614892,"name":"Naoki Takezako","orcid":null,"position":2,"is_corresponding":false},{"id":1614894,"name":"Akira Ohwada","orcid":null,"position":3,"is_corresponding":false},{"id":1614895,"name":"Takashi Kumagai","orcid":null,"position":4,"is_corresponding":false},{"id":1614896,"name":"Kaichi Nishiwaki","orcid":null,"position":5,"is_corresponding":false},{"id":1614899,"name":"Akira Horikoshi","orcid":null,"position":6,"is_corresponding":false},{"id":1560592,"name":"Tetsuya Fukuda","orcid":null,"position":7,"is_corresponding":false},{"id":1614902,"name":"Hina Takano","orcid":null,"position":8,"is_corresponding":false},{"id":1614904,"name":"Yasuji Kouzai","orcid":null,"position":9,"is_corresponding":false},{"id":1614905,"name":"Junji Tanaka","orcid":null,"position":10,"is_corresponding":false},{"id":128947,"name":"Satoshi Morita","orcid":null,"position":11,"is_corresponding":false},{"id":1614906,"name":"Junichi Sakamoto","orcid":null,"position":12,"is_corresponding":false},{"id":1614907,"name":"Hisashi Sakamaki","orcid":null,"position":13,"is_corresponding":false},{"id":1614909,"name":"Koiti Inokuchi","orcid":null,"position":14,"is_corresponding":false},{"id":1588800,"name":"Masayuki Shiseki","orcid":"0000-0002-7827-4971","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy","abstract":"BACKGROUND: With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the inhibition of BCR-ABL1 tyrosine kinase in vitro and more effective in CP-CML patients who do not achieve an optimal response with imatinib treatment. METHODS: In the present study, we attempted to investigate whether switching the treatment from imatinib to dasatinib can induce DMR in 16 CP-CML patients treated with imatinib for at least two years who achieved a major molecular response (MMR) with detectable levels of BCR-ABL1 transcripts. RESULTS: The rates of achievement of DMR at 1, 3, 6 and 12 months after switching to dasatinib treatment in the 16 patients were 44% (7/16), 56% (9/16), 63% (10/16) and 75% (12/16), respectively. The cumulative rate of achieving DMR at 12 months from initiation of dasatinib therapy was 93.8% (15/16). The proportion of natural killer cells and cytotoxic T cells in peripheral lymphocytes increased after switching to dasatinib. In contrast, the proportion of regulatory T cells decreased during treatment. The safety profile of dasatinib was consistent with previous studies. CONCLUSION: Switching to dasatinib would be a therapeutic option for CP-CML patients who achieved MMR but not DMR by imatinib, especially for patients who wish to discontinue TKI therapy.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28550414","pmcid":"PMC5608785","openalex_id":"https://openalex.org/W2618548116","authors":[],"funders":[],"total_grants":0,"fwci":0.1686,"citation_percentile":0.52205417,"influential_citations":0,"citation_trend":[{"year":2017,"count":1},{"year":2023,"count":1},{"year":2025,"count":2}],"oa_status":"hybrid","license":"other-oa","oa_locations":[{"url":"https://link.springer.com/content/pdf/10.1007%2Fs10147-017-1141-y.pdf","host_type":"journal"},{"url":"https://link.springer.com/content/pdf/10.1007%2Fs10147-017-1141-y.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1007/s10147-017-1141-y/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/s10147-017-1141-y.pdf","host_type":"publisher"},{"url":"https://doi.org/10.1007/s10147-017-1141-y","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28550414","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5608785","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC5608785","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC5608785?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Chronic Myeloid Leukemia Treatments","Eosinophilic Disorders and Syndromes","Garlic and Onion Studies","Adult","Aged","Dasatinib","Female","Fusion Proteins, bcr-abl","Gene Expression Regulation, Leukemic","Humans","Imatinib Mesylate","Killer Cells, Natural","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Leukemia, Myeloid, Chronic-Phase","Male","Middle Aged","Mutation","Protein Kinase Inhibitors","Treatment Outcome"],"mesh_terms":["Imatinib Mesylate","Dasatinib","Adult","Aged","Female","Humans","Killer Cells, Natural","Male","Middle Aged","Mutation","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Leukemia, Myeloid, Chronic-Phase","Gene Expression Regulation, Leukemic","Fusion Proteins, bcr-abl","Treatment Outcome","Protein Kinase Inhibitors"],"keywords":["Dasatinib","Imatinib","Medicine","Myeloid leukemia","Tyrosine kinase","Tyrosine-kinase inhibitor","Imatinib mesylate","Internal medicine","Oncology","Cancer research","Pharmacology","Cancer","Receptor","Chronic myeloid leukemia","Deep Molecular Response"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T04:30:24.726970Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}